Metformin: clinical use in type 2 diabetes

Area of Science:

• Endocrinology
• Pharmacology
• Nephrology

Background:

• Metformin is a leading oral glucose-lowering drug for type 2 diabetes mellitus (T2DM).
• Its mechanism of action, primarily reducing hepatic glucose production, is still debated.
• Widely recommended by guidelines (EASD, ADA) due to efficacy, cost, weight neutrality, and safety.

Purpose of the Study:

• To review the current understanding of metformin's role in T2DM management.
• To examine emerging data on metformin use in patients with chronic kidney disease (CKD).
• To discuss the potential challenges to metformin's 'foundation therapy' status.

Main Methods:

• Review of existing literature and clinical guidelines.
• Analysis of recent data regarding metformin's efficacy and safety in renal impairment.
• Comparison with newer glucose-lowering agents and their cardioprotective evidence.

Main Results:

• Metformin's benefits include efficacy, low cost, weight neutrality, and a good safety profile.
• Cardiovascular event reduction and improvements in lipids/inflammatory markers observed, potentially independent of glucose lowering.
• Lenient regulations now permit metformin use in mild to moderate stable CKD.

Conclusions:

• Metformin remains a cornerstone therapy for T2DM, with expanding indications in renal dysfunction.
• The lack of long-term comparative studies against newer agents may challenge its 'foundation therapy' status.
• Further research is needed to fully elucidate metformin's benefits and its place alongside newer antidiabetic drugs.